Jump to content

Igor Galynker

Add links
From Wikipedia, the free encyclopedia
Igor Galynker
Igor Galynker
Born
Moscow, USSR
OccupationPsychiatrist
Years active1988 - present
SpouseAsya Trakht
ChildrenBenjamin Galynker
Jaziah Galynker
Parent(s)Ilya Galynker
Raya Galynker

Igor Galynker is an American psychiatrist, clinician and researcher. His research interests include bipolar disorder, suicide prevention, and the role of family dynamics in psychiatric illness.[1][2] He has published on these topics both in professional journals[3] and in the lay press.[4][5] His recent research has been devoted to describing Suicide Crisis Syndrome (SCS), an acute suicidal cognitive-affective state predictive of imminent suicidal behavior.[6][7][8]

Galynker currently serves as the Associate Chairman for Research in the Department of Psychiatry at Mount Sinai Beth Israel, and is the Founder and Director of the Family Center for Bipolar Disorder and of the Mount Sinai Suicide Research and Prevention Laboratory. Since 2014, he has held the position of Professor of Psychiatry at the Icahn School of Medicine in New York City.[9]

Education and work in chemistry

[edit]

Galynker was born in Moscow, USSR. His mother, Raya, was an internist and his father, Ilya, was a professor of textile engineering. They met and married in Voronezh before World War II and moved to Moscow after the war ended. In 1971 Galynker graduated as from Moscow's Public School #109, and in 1976 he earned magna cum laude from the Department of Chemistry at Moscow State University.

He immigrated to the United States in 1978, and worked as a chemist researcher at the CIBA-Geigy corporation for a year. Then he pursued graduate studies (1978–1981) in organic synthesis under the mentorship of professor W. Clark Still at Columbia University. His PhD thesis, recognized with the Hammet Award for outstanding research, described the first use of computer modeling in organic synthesis and has subsequently been widely cited.[10] Following a fellowship in human genetics at the Columbia Presbyterian Medical Center, Galynker taught chemistry at Purdue University and at Columbia University.[11]

Work in psychiatry and Mount Sinai Beth Israel

[edit]

Galynker received his medical degree in 1988 from the Albert Einstein College of Medicine. He completed his psychiatry residency at Mount Sinai Medical Center. He has since worked at Beth Israel Medical Center in Manhattan (currently Mount Sinai Beth Israel), where he is the Associate Chairman for Research in the Department of Psychiatry and Behavioral Sciences.

Galynker Family Center for Bipolar Disorder

[edit]

In 2006, Dr. Galynker founded the Family Center for Bipolar Disorder (FCB), a clinical and research center providing mental health care for children, adolescents, and adults. The Center was profiled in the New York Times[12] and the Wall Street Journal.[13] In 2015, the Family Center for Bipolar was officially renamed the Richard and Cynthia Zirinsky Center for Bipolar, in honor of a gift from the Zirinsky Family. In 2021, the Center was renamed the Galynker Family Center for Bipolar Disorder.

Galynker Family Center for Hope and Healing

[edit]

Dr. Galynker founded the Galynker Family Center for Hope and Healing in 2024 as a clinical center for suicide prevention. The treatment approach is based on The Narrative Crisis Model of Suicide[14][15][16] and the Family Approach pioneered in the Family Center for Bipolar Disorder featured in the New York Times[17] and the Wall Street Journal.[18]

Other research

[edit]

Cognition

[edit]

While working as a resident psychiatrist, Galynker was the first to report that both hospital admissions from the ER[19] and the duration of hospital stay in the acute psychiatric unit[20] was influenced by cognition, suggesting that in addition to psychiatric symptoms, cognitive dysfunction should be a target of pharmacological intervention. This work anticipated later focus on treatment of cognitive dysfunction and cognitive training in schizophrenia and bipolar disorder[21][22] Galynker later reported on persistent cognitive deficits in opiate addicts in methadone maintenance treatment[23]

Addictions

[edit]

While in residency working at the Brookhaven National Laboratory, Galynker synthesized [11-C]-buprenorphine for use in PET studies of opiate addiction.[24] He later published PET studies of remitted opiate addicts which showed that cognitive deficits, negative affect, and abnormal glucose metabolism present during active drug use persisted for months and years after detoxification from methadone.[25][26][27] With Dr. Lisa Cohen, Galynker later showed that behavioral sex addicts, such as male pedophiles, had deficits in glucose metabolism in the temporal cortex and severe character pathology that was similar but broader and more pronounced than that of the opiate-dependent subjects. In a subsequent series of reports, Cohen and Galynker described character pathology of pedophiles and other sex offenders[28] and proposed a model for the etiology of pedophilic behavior.[29]

Mood disorders

[edit]

In 1998 Galynker published a widely cited SPECT study of cerebral perfusion in Major Depressive Disorder (MDD), which showed that in MDD, reduced cerebral blood flow was associated with negative symptoms rather than mood.[30] This was one of the first imaging studies to demonstrate that cerebral function was not related to a specific diagnosis but to symptoms, a finding which echoed Galynker's early findings on cognitive deficits and patient function, and anticipated the current NIMH Research Domain Criteria Project. Galynker was also the first to report (in a case series) that low dose quetiapine and risperidone were effective for treatment of depression and anxiety[31] a finding later supported by randomized clinical trials, leading to quetiapine approval for these indications.[32] Galynker has also contributed to research investigating racial disparities in diagnostic rates of bipolar disorder, finding that Black individuals are more likely than white patients to be diagnosed with schizophrenia rather than bipolar disorder.[33]

Suicide Prevention

[edit]

Since 2008, Dr. Galynker and his colleagues have been working on describing an acute suicidal mental state that precedes a suicide attempt. Their work has led to the formulation of the Narrative Crisis Model of Suicide.[34]  

Narrative Crisis Model of Suicide

[edit]

The Narrative Crisis Model of Suicide (NCM) is a comprehensive theoretical framework aimed at illustrating the complex dynamic contributing to suicidal behavior.[35][36][37] This model posits that individuals with an elevated baseline vulnerability to suicide may develop a Suicidal Narrative, a distorted perceptions of themselves, others and the world, when facing stressful life events.[38] The Suicidal Narrative consist of eight stages, such as difficulties disengaging from unrealistic goals, difficulties redirecting one’s efforts toward realistic goals, feelings of entitlement to happiness, social defeat, fear of humiliation, thwarted belongingness, perceived burdensomeness, and a perception of no future.[39] Anchored in long-term inter and intra-personal vulnerabilities these distorted cognitions may result in individuals perceiving them as having no future, where suicide is the only viable option.[40] The final stage of the NCM is the Suicide Crisis Syndrome.

Suicide Crisis Syndrome

[edit]

In 2010, with Dr. Zimri Yaseen Dr. Galynker introduced the concept of the Suicide Crisis Syndrome (SCS), initially known as Suicide Trigger State, a suicide-specific clinical entity, characterized by frantic hopelessness/entrapment, affective disturbance, loss of cognitive control, hyperarousal, and acute social withdrawal.[41] SCS was found to be strongly predictive of suicidal behavior within one-two months after discharge.[42][43][44][45] Importantly, the staple of current suicide risk assessment, suicidal ideation and intent may or may not be present.[8] The SCS diagnosis is currently under review by the DSM Steering Committee for inclusion in the Diagnostic and Statistical Manual of Mental Disorders.

In addition to the SCI, Galynker and colleagues have developed a multi-informant Modular Assessment of Risk for Imminent Suicide (MARIS).[46] MARIS has four independent assessment modules and is unique in that both patients and clinicians provide information. Clinicians' modules include their emotional responses to the SCS, which significantly improve predictive scale.[47][46] Both the SCS and the MARIS projects were funded by the American Foundation for Suicide Prevention.[48]

The SCS, the MARIS, and their clinical use are described in Galynker's recent textbook, "The Suicidal Crisis. Clinical Guide to the Assessment of Imminent Suicide Risk."[39]

In 2020, Northshore Healthcare System in Chicago implemented Dr. Galynker’s Suicide Crisis patient assessment measure (SCI-SF) and found it to be a preferred tool for guiding a clinical decision-making regarding the hospitalization of patients at risk of suicide.[49]  

Virtual Human Interaction for Emotional Self-Awareness Training

[edit]

This project developed by Dr. Galynker and colleagues employed Virtual Human technology to train clinicians in emotional self-awareness when working with suicidal patients, including their ability to recognize emotional responses and the ability to engage in empathetic verbal communication with acutely suicidal patients.[50] During the project, a Virtual Reality training method “Training Clinicians for Empathic Communication for Suicide Intervention 1.0 (TECSI-1) was introduced. The outcomes of TECSI-1 indicated improvement in empathic communication, a reduction in post-training suicidal ideation among patients, and enhanced patient-reported therapeutic alliance with their clinicians.[51][52][53] This project was funded by the NIH.[50]

Currently, Dr. Galynker and his team are focused on the development of the TECSI-2, incorporating new technologies such as Open AI ChatGPT to address previous technological limitations.

Advocacy and public awareness

[edit]

Galynker has been outspoken in his concerns about possible conflicts of interest between psychiatrists and the pharmaceutical industry. In 2005, he showed that the results of pharmaceutical trials published in even the most reputable scientific journals, JAMA Psychiatry and the American Journal of Psychiatry, systematically favored the drug produced by the manufacturer that paid for the study and disfavored the competitor.[54] This study was profiled on the front page of USA Today.[55]

Galynker has also been concerned with the harmful consequences of family exclusion from psychiatric treatment, which he associated with an increased risk of violence and suicide as well as poor outcomes[56][57] His opinions on the role of family (and staff) in preventing campus violence and reducing student suicide risks have been published by ABC News,[58] the New York Times,[59] and The Wall Street Journal.[60] Galynker has written a book, Talking to Families About Mental Illness, on how to involve family in psychiatric treatment, as well as an advice book on how to recognize the right romantic partner, "Choosing Right: A Psychiatrist's Guide to Starting a New Relationship" (ASIN B00C6D7BRE).

Recently, Galynker has been making media promoting the Narrative Crisis Model of Suicide and Suicidal Crisis Syndrome in assessing and treating imminent suicide risk. He has been interviewed by psychological blogs and appeared on multiple podcasts.

In 2021, the American Foundation for Suicide Prevention published a spotlight interview piece with Galynker, in which he discusses his career in suicide research and prevention.[61] On September 9, 2024, Galynker's opinion piece advocating for a paradigm shift in suicide prevention was published in the Chicago Tribune, highlighting the importance of transitioning to a more scientific, evidence-based approach.[62]

Photography

[edit]

In 2021, Dr. Galynker published his first street photography book WE,[63] which includes photographs of the Soviets and the New Yorkers, captured before and after his immigration to the US. He also maintains a street photography website featuring images taken across the globe.[64]

Books

[edit]
  • The Suicidal Crisis: Clinical Guide to the Assessment of Imminent Suicide Risk, 2nd edition[39]
  • Talking to Families about Mental Illness: What Clinicians Need to Know[1]
  • Choosing Right: A Psychiatrist's Guide To Starting A New Relationship[65]
  • WE[63]

Selected podcasts

[edit]
  • "The Suicidal Crisis." Medicating Normal.[66]
  • "Dr. Igor Galynker on Mental Health Care, Optimism, and Suicide Prevention".[67]  
  • "Why Do People Commit Suicide and How To Prevent It with Dr. Igor Galynker". Going Mental with Eileen Kelly.[68]

References

[edit]
  1. ^ a b Galynker, Igor (2011). Talking to Families About Mental Illness: What Clinicians Need to Know (1st ed.). New York: W. W. Norton and Company, Inc. ISBN 9780393706000. OCLC 658536694.
  2. ^ "Igor Galynker | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2019-10-25.
  3. ^ Cohen, Lisa J.; Grebchenko, Yuli F.; Steinfeld, Matthew; Frenda, Steven J.; Galynker, Igor I. (November 2008). "Comparison of Personality Traits in Pedophiles, Abstinent Opiate Addicts, and Healthy Controls: Considering Pedophilia as an Addictive Behavior". Journal of Nervous and Mental Disease. 196 (11): 829–837. doi:10.1097/NMD.0b013e31818b4e3d. ISSN 0022-3018. PMID 19008734. S2CID 1505984.
  4. ^ "Can Suicide Scales Predict a Future Suicide Attempt?". Elements Behavioral Health. October 16, 2011.
  5. ^ "Preventing suicide: What should clinicians do differently?". www.mdedge.com. Retrieved 2019-10-25.
  6. ^ "Can a New Diagnosis Help Prevent Suicide?". Undark Magazine. 2019-09-11. Retrieved 2019-10-25.
  7. ^ "Novel Suicide Prediction Tool Goes Beyond Patient Self-Reports". Medscape. Retrieved 2019-10-25.
  8. ^ a b Schuck, Allison; Calati, Raffaella; Barzilay, Shira; Bloch-Elkouby, Sarah; Galynker, Igor (May 2019). "Suicide Crisis Syndrome: A review of supporting evidence for a new suicide-specific diagnosis". Behavioral Sciences & the Law. 37 (3): 223–239. doi:10.1002/bsl.2397. ISSN 1099-0798. PMID 30900347. S2CID 85449010.
  9. ^ "Suicide Research and Prevention Laboratory |". labs.icahn.mssm.edu. Retrieved 2019-10-25.
  10. ^ Still, W C; Galynker, I (1981). "Chemical Consequences of Conformation in Macrocyclic Compounds" (PDF). Tetrahedron. 37 (23): 3981–3996. doi:10.1016/s0040-4020(01)93273-9.
  11. ^ Rosenblatt, Gary. "Treating Bipolar Disorder: It Takes A Family". jewishweek.timesofisrael.com. Retrieved 2019-10-25.
  12. ^ Hartocollis, A (June 4, 2008). "Clinic Treats Mental Illness by Enlisting the Family". The New York Times'. Retrieved March 19, 2014.
  13. ^ Tsuei, Christina (April 14, 2011). "Shedding Light on Bipolar Disorder" (video). Wall Street Journal.
  14. ^ Cohen, LJ; et al. (October 2018). "Suicide Crisis Syndrome Mediates the Relationship Between Long-term Risk Factors and Lifetime Suicidal Phenomena". Suicide Life Threat Behav. 48 (5): 613–623. doi:10.1111/sltb.12387. PMID 28833408. S2CID 7617638
  15. ^ Cohen, LJ; et al. (April 2019). "The Suicidal Narrative and Its Relationship to the Suicide Crisis Syndrome and Recent Suicidal Behavior". Suicide Life Threat Behav. 49 (2): 413–422. doi:10.1111/sltb.12439. PMID 29397571. S2CID 27452371
  16. ^ Bloch-Elkouby, Sarah; Gorman, Bernard; Lloveras, Lauren; Wilkerson, Timothy; Schuck, Allison; Barzilay, Shira; Calati, Raffaella; Schnur, David; Galynker, Igor (2020-12-01). "How do distal and proximal risk factors combine to predict suicidal ideation and behaviors? A prospective study of the narrative crisis model of suicide". Journal of Affective Disorders. 277: 914–926. doi:10.1016/j.jad.2020.08.088. ISSN 0165-0327
  17. ^ Hartocollis, A (June 4, 2008). "Clinic Treats Mental Illness by Enlisting the Family". The New York Times'. Retrieved March 19, 2014.
  18. ^ Tsuei, Christina (April 14, 2011). "Shedding Light on Bipolar Disorder" (video). Wall Street Journal.
  19. ^ Galynker, I; Harvey, P (1992). "Neuropsychological screening in the psychiatric emergency room". Comprehensive Psychiatry. 33 (5): 291–295. doi:10.1016/0010-440x(92)90035-o. PMID 1395548.
  20. ^ Kato, K; Galynker, I; et al. (1995). "Cognitive impairment in psychiatric patients and length of hospital stay". Comprehensive Psychiatry. 36 (3): 213–217. doi:10.1016/0010-440x(95)90084-9. PMID 7648845.
  21. ^ Kroken, RA; Loberg, EM; et al. (2014). "A critical review of pro-cognitive drug treatments in psychosis: convergence on myelination and inflammation". Front Psychiatry. 5: 11. doi:10.3389/fpsyt.2014.00011. PMC 3912739. PMID 24550848.
  22. ^ Kumar, CT; Frangou, S (2010). "Clinical implications of cognitive function in bipolar disorder". Ther Adv Chronic Dis. 1 (3): 85–93. doi:10.1177/2040622310374678. PMC 3513860. PMID 23251731.
  23. ^ Prosser, J; London, E; Galynker, I (2009). "Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results". Drug and Alcohol Dependence. 104 (3): 228–240. doi:10.1016/j.drugalcdep.2009.04.022. PMID 19608356.
  24. ^ Galynker, I; Schlyer, D; et al. (1996). "In vivo studies of 11-C-buprenorphine in mice and baboons". J Nucl Med Biol. 23 (3): 325–331. doi:10.1016/0969-8051(95)02087-X. PMID 8782244.
  25. ^ Prosser, J; London, ED; Galynker, II (2009). "Sustained Attention in Patients Receiving and Abstinent Following Methadone Maintenance Treatment for Opiate Dependence: Performance and Neuroimaging Results". Drug Alcohol Depend. 104 (3): 228–40. doi:10.1016/j.drugalcdep.2009.04.022. PMID 19608356.
  26. ^ Galynker, I; Eisenberg, D; et al. (2007). "Cerebral Metabolism and Mood in Remitted Opiate Dependence". Drug Alcohol Depend. 90 (2–3): 166–174. doi:10.1016/j.drugalcdep.2007.03.015. PMC 2063442. PMID 17521829.
  27. ^ Prosser, J; Cohen, LJ; et al. (2006). "Neuropsychological functioning in opiate-dependent subjects receiving and following methadone-maintenance treatment". Drug Alcohol Depend. 84 (3): 240–7. doi:10.1016/j.drugalcdep.2006.02.006. PMC 2067988. PMID 16545923.
  28. ^ Cohen, L; Galynker, I (2002). "Clinical features of pedophilia and implications for treatment". Journal of Psychiatric Practice. 8 (5): 276–289. doi:10.1097/00131746-200209000-00004. PMID 15985890. S2CID 22782583.
  29. ^ Cohen, L; Nikiforov, K; et al. (2002). "Heterosexual male perpetrators of childhood sexual abuse: a preliminary neuropsychiatric model". Psychiatric Quarterly. 73 (4): 313–336. doi:10.1023/A:1020416101092. PMID 12418359. S2CID 44216270.
  30. ^ Galynker, I; Cai, J; et al. (1998). "Hypofrontality and negative symptoms in major depressive disorder". Journal of Nuclear Medicine. 39 (4): 608–612. PMID 9544664.
  31. ^ Galynker, I; Khan, A; et al. (2005). "Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression". The Journal of Clinical Psychiatry. 66 (544): 2005. doi:10.4088/jcp.v66n0420f. PMID 15816805.
  32. ^ "Quetiapine". MedlinePlus. U.S. National Library of Medicine.
  33. ^ Galynker, I; Cohen, L; et al. (2011). "Disparities in diagnosis of bipolar disorder in individuals of African and European descent: a review". Journal of Psychiatric Practice. 17 (6): 394–403. doi:10.1097/01.pra.0000407962.49851.ef. PMID 22108396. S2CID 1878317.
  34. ^ Cohen, Lisa Janet; Mokhtar, Radwa; Richards, Jenelle; Hernandez, Michelle; Bloch-Elkouby, Sarah; Galynker, Igor (April 2022). "The Narrative-Crisis Model of suicide and its prediction of near-term suicide risk". Suicide & Life-Threatening Behavior. 52 (2): 231–243. doi:10.1111/sltb.12816. ISSN 1943-278X. PMID 34766360.
  35. ^ Li, S; et al. (January 8, 2018). "Entrapment as a mediator of suicide crises". BMC Psychiatry. 18 (1): 4. doi:10.1186/s12888-018-1587-0. PMC 5759206. PMID 29310622.
  36. ^ Cohen, LJ; et al. (October 2018). "Suicide Crisis Syndrome Mediates the Relationship Between Long-term Risk Factors and Lifetime Suicidal Phenomena". Suicide Life Threat Behav. 48 (5): 613–623. doi:10.1111/sltb.12387. PMID 28833408. S2CID 7617638.
  37. ^ Cohen, LJ; et al. (April 2019). "The Suicidal Narrative and Its Relationship to the Suicide Crisis Syndrome and Recent Suicidal Behavior". Suicide Life Threat Behav. 49 (2): 413–422. doi:10.1111/sltb.12439. PMID 29397571. S2CID 27452371.
  38. ^ Bloch-Elkouby, Sarah; Gorman, Bernard; Lloveras, Lauren; Wilkerson, Timothy; Schuck, Allison; Barzilay, Shira; Calati, Raffaella; Schnur, David; Galynker, Igor (2020-12-01). "How do distal and proximal risk factors combine to predict suicidal ideation and behaviors? A prospective study of the narrative crisis model of suicide". Journal of Affective Disorders. 277: 914–926. doi:10.1016/j.jad.2020.08.088. ISSN 0165-0327.
  39. ^ a b c Galynker, Igor (April 4, 2023). The suicidal crisis: clinical guide to the assessment of imminent suicide risk (2nd ed.). New York, NY: Oxford University Press. ISBN 9780197582718. OCLC 1006517247.
  40. ^ Cohen, Lisa Janet; Gorman, Bernard; Briggs, Jessica; Jeon, Min Eun; Ginsburg, Tal; Galynker, Igor (April 2019). "The Suicidal Narrative and Its Relationship to the Suicide Crisis Syndrome and Recent Suicidal Behavior". Suicide & Life-Threatening Behavior. 49 (2): 413–422. doi:10.1111/sltb.12439. ISSN 1943-278X. PMID 29397571.
  41. ^ Calati, Raffaella; Nemeroff, Charles B.; Lopez-Castroman, Jorge; Cohen, Lisa J.; Galynker, Igor (2020-04-21). "Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper". The International Journal of Neuropsychopharmacology. 23 (3): 192–205. doi:10.1093/ijnp/pyz063. ISSN 1469-5111. PMC 7171927. PMID 31781761.
  42. ^ Bafna, Anokhi; Rogers, Megan L.; Galynker, Igor I. (2022-12-01). "Predictive validity and symptom configuration of proposed diagnostic criteria for the Suicide Crisis Syndrome: A replication study". Journal of Psychiatric Research. 156: 228–235. doi:10.1016/j.jpsychires.2022.10.027. ISSN 0022-3956.
  43. ^ Yaseen, Z; Gilmer, E; et al. (September 12, 2012). "Emergency room validation of the revised suicide trigger scale (STS-3): a measure of a hypothesized trigger state". PLOS ONE. 7 (9): e45157. doi:10.1371/journal.pone.0045157. PMC 3443232. PMID 23024805.
  44. ^ Yaseen, Z; Kopeykina, I; et al. (January 21, 2014). "Predictive Validity of the Suicide Trigger Scale (STS-3) for Post-Discharge Suicide Attempt in High-Risk Psychiatric Inpatients". PLOS ONE. 9 (1): e86768. Bibcode:2014PLoSO...986768Y. doi:10.1371/journal.pone.0086768. PMC 3897755. PMID 24466229.
  45. ^ Galynker, I; et al. (February 2017). "Prediction of suicidal behavior in high risk psychiatric patients using an assessment of acute suicidal state: The suicide crisis inventory". Depress Anxiety. 34 (2): 147–158. doi:10.1002/da.22559. PMID 27712028. S2CID 44405255.
  46. ^ a b Hawes, M; et al. (January 2017). "The Modular Assessment of Risk for Imminent Suicide (MARIS): A proof of concept for a multi-informant tool for evaluation of short-term suicide risk". Compr Psychiatry. 72: 88–96. doi:10.1016/j.comppsych.2016.10.002. PMID 27771563.
  47. ^ Yaseen, Z; et al. (July 2017). "Clinicians' conflicting emotional responses to high suicide-risk patients-Association with short-term suicide behaviors: A prospective pilot study". Compr Psychiatry. 76: 69–78. doi:10.1016/j.comppsych.2017.03.013. PMID 28431270.
  48. ^ "The Focus Grant: Modular Assessment of Risk for Imminent Suicide: A Novel Tool for Suicide Prediction". American Foundation for Suicide Prevention. Archived from the original on February 24, 2016.{{cite web}}: CS1 maint: unfit URL (link)
  49. ^ Karsen, Ethan; Cohen, Lisa J.; White, Betsy; De, Gabriele P.; Goncearencoa, Inna; Galynker, Igor I.; Miller, Frederick E. (2023-05-01). "Impact of the Abbreviated Suicide Crisis Syndrome Checklist on Clinical Decision Making in the Emergency Department". The Journal of Clinical Psychiatry. 84 (3): 22m14655. doi:10.4088/JCP.22m14655. ISSN 1555-2101. PMID 37134117.
  50. ^ a b "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 2023-09-20.
  51. ^ Sarli G., Rogers M. L., Bloch-Elkouby S., Lawrence O. C., Gomes De Siqueira A. Yao H., Lok B.c Foster A., Galynker I. Using Virtual Patients to Assess and Improve Clinicians' Emotional Self-Awareness: A Randomized Controlled Study (Acad Psychiatry, accepted provisionally)
  52. ^ Sarli G., Bloch-Elkouby, S., Gomes de Siqueira, A., Yao, H., Lok B., & Galynker, I. Patients’ Suicidal Outcomes after Clinicians’ Empathetic Communication Training: the TECSI Pilot Study (in preparation).
  53. ^ Yao H, Bloch-Elkouby, S., Gomes de Siqueira, Lawrence O., A., Lok B., & Galynker, I. Do real-time instructions during virtual human interaction clinician training in empathic communication when working with suicidal patients improve training efficacy? (in preparation)
  54. ^ Kelly, R; Cohen, L; et al. (2006). "Relationship between drug company funding and outcomes of clinical psychiatric research". Psychological Medicine. 36 (1647): 1647–56. doi:10.1017/s0033291706008567. PMID 16893480. S2CID 20645491.
  55. ^ Elias, Marilyn (May 24, 2006). "Psychiatric drugs fare favorably when companies pay for studies". USA Today.
  56. ^ Miklowitz, DJ; Scott, J (2009). "Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions". Bipolar Disorders. 2: 110–122. doi:10.1111/j.1399-5618.2009.00715.x. PMID 19538690. S2CID 31496082.
  57. ^ Moreno, DH; Bio, DS; et al. (2012). "Burden of maternal bipolar disorder on at-risk offspring: a controlled study on family planning and maternal care". Journal of Affective Disorders. 143 (1–3): 172–8. doi:10.1016/j.jad.2012.05.050. PMID 22877968.
  58. ^ Galynker, I (August 30, 2007). "Four months after the massacre, lessons to be learned". ABC News. Retrieved March 31, 2014.
  59. ^ Galynker, I. (May 6, 2013). "Opinion: A Rise in Suicide Among Baby Boomers". The New York Times. Retrieved March 31, 2014.
  60. ^ Moreno, DH; Bio, DS; Petresco, S; Petresco, D; Gutt, EK; Soeiro-de-Souza, MG; Moreno, RA (2012). "Burden of maternal bipolar disorder on at-risk offspring: a controlled study on family planning and maternal care". J Affect Disord. 143 (1–3): 172–8. doi:10.1016/j.jad.2012.05.050. PMID 22877968..
  61. ^ "Dr. Igor Galynker: An AFSP Research Spotlight Interview". 28 September 2021.
  62. ^ Galynker, Igor (2024-09-09). "Dr. Igor Galynker: To prevent suicide, we have to change to a scientific approach". Chicago Tribune. Retrieved 2024-12-14.
  63. ^ a b Galynker, Igor (2021-01-01). WE. Passage Press. ISBN 978-0-578-99337-9.
  64. ^ "Igor Galynker Photography". Dr. Igor Galynker. Retrieved 2023-09-20.
  65. ^ Galynker, Igor (2013-04-02). Kopeykina, Irina (ed.). Choosing Right: A Psychiatrist's Guide To Starting A New Relationship. Ilbena Inc.
  66. ^ A Conversation w/ Igor Galynker, M.D., PhD - "The Suicidal Crisis", 25 August 2023, retrieved 2023-09-20
  67. ^ "87: Dr. Igor Galynker on Mental Healthcare, Optimism and Suicide Prevention - The Madhappy Podcast". iHeart. Retrieved 2023-09-20.
  68. ^ Going Mental with Eileen Kelly. "Why Do People Commit Suicide and How To Prevent It with Dr. Igor Galynker". music.amazon.com. Retrieved 2023-09-20.
Retrieved from "http://en.wiki.x.io/w/index.php?title=Igor_Galynker&oldid=1265580203"